Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Autor:	W S Pipe, WG F Leebeek, M Recht, S N Key, S Lattimore, G Castaman, M Coppens, D Cooper, R Gut, S Slawka, S Verweij, R Dolmetsch, Y Li, PE Monahan, W Miesbach
Rok vydání:	2023
Zdroj:	GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark.
ISSN:	2567-5761
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c0ecd0893aca3fb1a528b355020deab6 https://doi.org/10.1055/s-0042-1760523 Zobrazit plný text záznamu